# Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.

> **NCT01908621** · PHASE3 · COMPLETED · sponsor: **Maria Sklodowska-Curie National Research Institute of Oncology** · enrollment: 90 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** G-CSF (filgrastim)
- **DRUG:** Cytosine arabinoside + G-CSF (filgrastim)

## Key facts

- **NCT ID:** NCT01908621
- **Lead sponsor:** Maria Sklodowska-Curie National Research Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-20
- **Primary completion:** 2016-03-18
- **Final completion:** 2017-10-27
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2018-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01908621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01908621, "Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01908621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*